Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome‐wide shRNA screen

Therapeutic effectiveness against metastatic or even locally advanced pancreatic ductal adenocarcinoma (PDAC) is dismal, with 5‐year survival less than 5%. Even in patients who undergo potentially curative resection, most patients' tumors recur in the liver. Improving therapies targeting or pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurahara, Hiroshi, Bohl, Christopher, Natsugoe, Shoji, Nishizono, Yuka, Harihar, Sitaram, Sharma, Rahul, Iwakuma, Tomoo, Welch, Danny R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Genetics and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867126/
https://www.ncbi.nlm.nih.gov/pubmed/27012470
http://dx.doi.org/10.1002/ijc.30110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867126/
https://www.ncbi.nlm.nih.gov/pubmed/27012470
http://dx.doi.org/10.1002/ijc.30110

Ejemplares similares